MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
215.63
-0.71
-0.33%
After Hours: 215.35 -0.28 -0.13% 17:20 03/28 EDT
OPEN
217.36
PREV CLOSE
216.34
HIGH
217.57
LOW
214.00
VOLUME
1.91M
TURNOVER
0
52 WEEK HIGH
319.76
52 WEEK LOW
211.02
MARKET CAP
31.34B
P/E (TTM)
27.04
1D
5D
1M
3M
1Y
5Y
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 10h ago
QQQ ETF Update, 3/28/2024 
TipRanks · 14h ago
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
TipRanks · 1d ago
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
NASDAQ · 2d ago
Forecasting The Future: 18 Analyst Projections For Biogen
Biogen has an average 12-month price target of $302.44. 18 analysts have recently shared their evaluations of Biogen. Biogen's stock has declined 5.59% in the last three months. The company has several drug candidates in phase 3 trials. The firm has a market capitalization below its peers.
Benzinga · 3d ago
Biogen Price Target Maintained With a $340.00/Share by Truist Securities
Dow Jones · 3d ago
Truist Securities Reiterates Buy on Biogen, Maintains $340 Price Target
Benzinga · 3d ago
BUZZ-Dyne slides after appointing new CEO
Shares of Dyne Therapeutics fall 11.5% to $25 premarket. Dyne appoints John Cox as CEO. Stock has more than doubled in the last 12 months. Shares of muscle disease specialist doubled in January after drug showed promise in early-stage trial.
Reuters · 3d ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.